Which treatment option is often included in the management of Myasthenia Gravis?

The management of Myasthenia Gravis (MG) frequently includes medications that improve neuromuscular transmission, which addresses the underlying issue in this autoimmune neuromuscular disorder. Myasthenia Gravis is characterized by weakness and rapid fatigue of voluntary muscles due to a breakdown in communication between nerves and muscles. This breakdown is primarily caused by the autoimmune response that targets acetylcholine receptors at the neuromuscular junction, leading to impaired transmission.

Medications such as acetylcholinesterase inhibitors (e.g., pyridostigmine) are commonly used. These drugs work by inhibiting the enzyme acetylcholinesterase, which normally breaks down acetylcholine. By prolonging the action of acetylcholine at the neuromuscular junction, these medications enhance communication between nerves and muscles, effectively improving muscle strength and endurance in patients with MG.

While other options like invasive surgery might be considered for specific individuals, for instance, thymectomy in cases where the thymus gland is involved, these are not first-line treatments. Cognitive Behavioral Therapy and athletic training do not directly address the neuromuscular transmission issues central to the condition, making them less relevant in the context of immediate treatment for MG. Therefore, medications that improve